Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 6/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | METTL3 | Q86U44 | 5/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30372943 | 0.86 | SRC (0.43) | SRCADKSLC29A1CA12CA1 | |
| SCHEMBL20911835 | 0.86 | SRC (0.43) | SRCADKSLC29A1CA12CA1 | |
| SCHEMBL22086335 | 0.84 | SRC (0.39) | SRCADKCA12CA1CA2 | |
| SCHEMBL22084741 | 0.82 | SRC (0.48) | SRCADKSLC29A1CA12CA1 | |
| SCHEMBL30295169 | 0.82 | SRC (0.48) | SRCADKSLC29A1CA12CA1 | |
| SCHEMBL22084740 | 0.81 | SRC (0.49) | SRCADKSLC29A1CA12CA1 | |
| SCHEMBL30372874 | 0.80 | SRC (0.42) | SRCADKSLC29A1CA12CA1 | |
| SCHEMBL29484482 | 0.78 | SRC (0.50) | SRCADKSLC29A1CA12CA1 | |
| SCHEMBL22084739 | 0.78 | SRC (0.50) | SRCADKSLC29A1CA12CA1 | |
| SCHEMBL22032001 | 0.76 | SRC (0.50) | SRCADKSLC29A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891158-B1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-12247045-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| US-20230055250-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-02-23 | — | — | US | disclosed |
| US-20230055250-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-02-23 | — | — | US | disclosed |
| EP-3891158-A1 | MAP4K4 INHIBITORS | Imperial College of Science, Technology and Medicine (GB) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020115481-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020115481-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055250-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K5, MAP4K1 | SRC 739/4885ADK 618/4885SLC29A1 4139/4885 |
| US-12247045-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K5, MAP4K1 | SRC 739/4885ADK 618/4885SLC29A1 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.